Other Respiratory and Intrathoracic Organs

Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for Hospitalized Adult Patients With COVID-19

The primary objectives are: To evaluate the efficacy of REGN10933+REGN10987 compared to placebo. To exclude futility of REGN10933+REGN10987 compared to placebo, as measured by death or mechanical ventilation To evaluate the safety and tolerability of REGN10933+REGN10987 compared to placebo Phase 2 (Cohort 1A) To evaluate the clinical efficacy of REGN10933+REGN10987 compared to placebo, as measured by death or mechanical ventilation To evaluate the safety and tolerability of REGN10933+REGN10987 compared to placebo Phase 3 (Cohort 1 and Cohort 1A) To evaluate the clinical efficacy of REGN10

PRESCO (Predictors of Severe COVID-19 Outcomes)

This is a longitudinal, multi-center, observational study collecting diverse biological measurements and clinical and epidemiological data for the purpose of enabling a greater understanding of the onset of severe outcomes, primarily acute respiratory distress syndrome (ARDS) and/or mortality, in patients presenting to the hospital with suspicion or diagnosis of COVID-19. We seek to understand whether there are early signatures that predict progression to ARDS, mortality, and/or other comorbid conditions. The duration of the study participation is approximately 3 months.

Viral Infection and Respiratory Illness Universal Study[VIRUS]: COVID-19 Registry (COVID-19)

Investigators aim is to create a real time COVID-19 registry of current ICU/hospital care patterns to allow evaluations of safety and observational effectiveness of COVID-19 practices and to determine the variations in practice across hospitals. Such a set of standards would increase the quality of single and multi-center studies, national registries as well as aggregation syntheses such as meta-analyses. It will also be of utmost importance in tiring times of public health emergencies and will help understand practice variability and outcomes during COVID-19 pandemic.

Community-Engagement Research Alliance (CEAL) Against COVID-19 in Disproportionately Affected Communities

•Aim 1: To conduct community-engaged research and data-driven targeted outreach of “at-risk” census blocks to assess and track barriers and facilitators for uptake of COVID-19 vaccines over time among members of Arizona’s Latino, American Indian, and African American communities.

BLUE - CORAL (Biology and Longitudinal Epidemiology of PETAL COVID-19 Observational Study)

Biology and Longitudinal Epidemiology of PETAL COVID-19 Observational Study. This study aims to identify acute and critically ill COVID-19 patients and collect detailed data during and after hospitalization in order to increase understanding of COVID-19

COVID - PACT (Prevention of Arteriovenous Thrombotic Events in Critically-Ill COVID-19 Patients Trial)

This is a multicenter, open-label, 2x2 factorial, randomized-controlled trial in critically-ill patients with novel coronavirus disease 2019 (COVID-19) evaluating the efficacy and safety of full-dose vs. standard prophylactic dose anticoagulation and of antiplatelet vs. no antiplatelet therapy for prevention of venous and arterial thrombotic events.

ACTIV-3

A Multicenter, Adaptive, Randomized, Blinded Controlled Trial of the Safety and Efficacy of Investigational Therapeutics for Hospitalized Patients with COVID-19
Subscribe to RSS - Other Respiratory and Intrathoracic Organs